In the world of medicine, research takes place day in day out. Because various illnesses have proved to be quite a menace over the years, scientists have always dedicated their time and energy towards finding appropriate remedies. Among the diseases that have been tough to treat are such as cancer. Nevertheless, Clay Siegall, in conjunction with Seattle Genetics has been working round the clock to find suitable remedies that can treat cancer effectively.
Seattle Genetics has been interacting with human antibodies over the years. The company has been manipulating and studying the human antibodies with the sole aim of producing drugs. Founded in 1998 by Clay Siegall, the company has been able to pioneer groundbreaking research over the years. Regarding research that involves human antibodies, Seattle Genetics has been able to come up with an antibody that can interact with cancer cells and infuse them with toxins that will, in turn, destroy the cancer cells from within. In turn, the antibodies will not harm the surrounding cells in any manner.
More about Seattle Genetics
Such a form of research could easily earn Seattle Genetics a remarkable reputation concerning the pharmaceutical industry. Keeping in mind that Seattle’s biotech community has been experiencing many ups and downs, there is high hope that Seattle Genetics is here to stay. With a market value of $10 billion and a workforce comprising of 900 employees, Seattle Genetics is ranked as the largest biotech company in Washington. Under the leadership of Clay Siegall, the pharmaceutical company has the ambition of upgrading to being a big pharma company with time. As a company that invests heavily when it comes to marketing as well as research, they are set to add 200 employees to their current workforce this year.
Of late, Seattle Genetics has launched a drug known as Adcetris. Adcetris is a drug that is aimed at treating Hodgkin lymphoma. Hodgkin lymphoma is cancer associated with the lymph system, and it can spread to other organs as well. If the drugs prove to be effective, it will be released into the market.
Clay Siegall has stated that Seattle Genetics is a multiproduct company that specializes in oncology and also operates on a global scale. The research that has been carried out by Seattle Genetics over the years has come in handy when it comes to drug production. There is no desire to sell Seattle Genetics to a larger company since the company is highly dedicated towards achieving greater heights.
Although Seattle Genetics had to sell its international commercial rights to Takeda Oncology back in the day, the capital that was raised was put to good use, and Adcetris was produced eventually. Since Clay Siegall was also able to gain more knowledge concerning global markets, he recently launched an office in Switzerland and Seattle Genetics is now able to carry out their own international marketing.
Under the leadership of Clay Siegall, Seattle Genetics will head far and wide. As an exemplary leader, Clay Siegall’s ability to steer the company in the right direction has led the company to where it is right now.